Top Abstract Purchase Related
Home
>
Node
>
Subnode

Economics of prostate cancer: a computer model

Grover, S.A..

Canadian Journal of Urology 4(2 Supp 1: 88-89

1997

ISSN/ISBN: 1195-9479
PMID: 12735845
Document Number: 475544
The economic impact of health care for prostate cancer represents a substantial and growing burden to Canadian society. To better allocate increasingly scarce health care resources will require a comprehensive understanding of the costs and benefits of specific diagnostic and therapeutic interventions to manage this disease. A detailed health economic model of prostate cancer care, currently under development, will be described in this article. Using a decision analytic approach we will integrate current clinical trial data, epidemiologic data of disease progression, and Canadian health care cost data to build a Markov model of prostate cancer care. The final model will support cost-effectiveness analyses to compare competing strategies for screening and treating patients with this disease.

Document emailed within 1 workday
Secure & encrypted payments

Agarwal, M.M.; Mandal, A.K.; Khandelwal, N.; Singh, S.K. 2007: Need for measurement of bone mineral density in patients of prostate cancer before and after orchidectomy: role of quantitative computer tomography Journal of the Association of Physicians of India 55: 486-490
Deckner, R. 1980: Economics of computer tomography Rontgenpraxis; Zeitschrift für Radiologische Technik 33(9): 209-215
Macdonald, R J. 2012: On the Role of Paradigms in Finance; From Economics Imperialism to Freakonomics: The Shifting Boundaries between Economics and Other Social Sciences; Economics Versus Human Rights Review of Social Economy 70(1): 134-141
Ross, R.K.; Pike, M.C.; Coetzee, G.A.; Reichardt, J.K.; Yu, M.C.; Feigelson, H.; Stanczyk, F.Z.; Kolonel, L.N.; Henderson, B.E. 1998: Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility Cancer Research 58(20): 4497-4504
Yee, C.S.; Kamradt, J.M.; Nielsen, L.C.; Panvinchian, R.; Pienta, K.J. 1998: Carboplatin-induced cell death in model prostate cancer systems Anticancer Research 18(6a): 4475-4482
Lin, S.H.; Pu, Y.S.; Luo, W.; Wang, Y.; Logothetis, C.J. 1999: Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model Anticancer Research 19(1a): 337-340
Xiao, W.-j.; Ye, D.-w.; Yao, X.-d.; Zhang, S.-l.; Dai, B.; Wang, Z.-f.; Wang, J.; Zhang, H.-l.; Shen, Y.-j.; Zhu, Y.; Zhu, Y.-p.; Shi, G.-h.; Ma, C.-g.; Qin, X.-j.; Lin, G.-w. 2010: Establishment of regression model predicting the probability of the capsular penetration of prostate cancer Zhonghua Yi Xue Za Zhi 90(42): 2976-2979
Neumann, H.G.; Seidenschnur, G.; Hofmann, H.; Schrodt, U.; Kühnert, M. 1972: Model for computer based mass-screening of the female population for early diagnosis of cervix cancer Das Deutsche Gesundheitswesen 27(37): 1762-1768
Herring, P.; Ingels, J.; Carbone, L.D.; Barrow, K.D.; Osborn, D.; Dietzen, D.J.; Pifer, L. 2003: Lack of efficacy of the combination of pamidronate and vitamin D on regression of prostate cancer in the Dunning rat model Journal of Environmental Pathology Toxicology and Oncology: Official Organ of the International Society for Environmental Toxicology and Cancer 22(2): Vii-Viii
Makinde, A.Y.; Luo-Owen, X.; Rizvi, A.; Crapo, J.D.; Pearlstein, R.D.; Slater, J.M.; Gridley, D.S. 2009: Effect of a metalloporphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation Anticancer Research 29(1): 107-118
Murray, N.P.; Aedo, S.óc.; Reyes, E.; Fuentealba, C.; Jacob, O. 2019: Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy Archivos Espanoles de Urologia 72(1): 16-24
Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Andersen, M.E. 2003: Computer demonstration of physiological-toxicokinetic models: demonstrating a computer model that simulates the estradiol (E2)-primed Lh surge during proestrus in the rat Toxicology Letters 138(1-2): 179
Van Steenbrugge, G.J.; Groen, M.; Bolt-de Vries, J.; Romijn, J.C.; Schroeder, F.H. 1985: Human prostate cancer (PC-82) in nude mice: a model to study androgen regulated tumor growth Progress in Clinical and Biological Research 185a: 23-50
Sun, S.-C.; Zhao, H.; Liu, R.; Wang, B.-L.; Liu, Y.-Q.; Zhao, Y.; Shi, Z.-D. 2017: Expression of long non-coding RNA H19 in prostate cancer and its effect on the proliferation and glycometabolism of human prostate cancer cells Zhonghua Nan Ke Xue 23(2): 120-124
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Grosclaude, P.; Menegoz, F.; Schaffer, P.; Macé Lesec'h, J.; Arveux, P.; Le Mab, G.; Soulié, M.; Villers, A. 1997: Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990 Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(4): 647-654
Pollard, M.; Luckert, P.H. 1990: In vivo model systems for assessing an anti-cancer drug: responses of autochthonous and transplanted prostate tumors to cyclophosphamide Anticancer Research 10(1): 33-36
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747
Liu, J-he.; Li, H-wei.; Tong, M.; Li, M.; Na, Y-qun. 2004: Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer Zhonghua Yi Xue Za Zhi 84(5): 364-368